Holen Sie sich die Stockscreener-App
18.57
0.65%
0.12
Handel nachbörslich:
18.57
Newamsterdam Pharma Company Nv Aktie (NAMS) Neueste Nachrichten
NewAmsterdam Pharma (NASDAQ:NAMS) Now Covered by Citigroup - Defense World
Citi initiates NewAmsterdam Pharma stock with buy rating on cholesterol drug - Investing.com Nigeria
Citi initiates NewAmsterdam Pharma stock with buy rating on cholesterol drug By Investing.com - Investing.com South Africa
Citi Recommends NewAmsterdam Pharma (NAMS) with a Strong Outlook | NAMS Stock News - GuruFocus
How the (NAMS) price action is used to our Advantage - news.stocktradersdaily.com
Stifel initiates NewAmsterdam stock with Buy rating, $44 target By Investing.com - Investing.com Nigeria
NewAmsterdam Pharma’s SWOT analysis: stock poised for cardiovascular breakthrough By Investing.com - Investing.com South Africa
NewAmsterdam Pharma’s SWOT analysis: stock poised for cardiovascular breakthrough - Investing.com
NewAmsterdam Pharma’s (NAMS) “Buy” Rating Reaffirmed at Needham & Company LLC - Defense World
NAMS: Needham Reiterates Buy Rating and Maintains Price Target | - GuruFocus
Cantor Fitzgerald maintains NewAmsterdam Pharma stock rating on trial data By Investing.com - Investing.com India
NewAmsterdam Pharma stock maintains buy rating at Stifel on strong data - Investing.com Nigeria
Cantor Fitzgerald maintains NewAmsterdam Pharma stock rating on trial data - Investing.com
California State Teachers Retirement System Raises Position in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
13 Biotech Stocks with Huge Upside Potential - Insider Monkey
NewAmsterdam Pharma Company N.V. (NAMS) Initiated with a Buy at Stifel - Insider Monkey
Transcript : NewAmsterdam Pharma Company N.V.Special Call - MarketScreener
Frazier Lifesciences Acquisition : NewAmsterdam Pharma R&D Day 2025 - MarketScreener
NewAmsterdam Pharma Schedules R&D Day for June 2025 - TipRanks
Brokers Set Expectations for NAMS FY2026 Earnings - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Coverage Initiated by Analysts at Stifel Nicolaus - Defense World
Kalkine: NewAmsterdam Pharma Progress in Nasdaq Index Spotlight Event - Kalkine Media
(NAMSW) Technical Pivots with Risk Controls - news.stocktradersdaily.com
NewAmsterdam Pharma (NAMS): Stifel Initiates Coverage with Buy Rating | NAMS Stock News - GuruFocus
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Analysts Just Trimmed Their Revenue Forecasts By 14% - simplywall.st
Analysts Have Just Cut Their NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Revenue Estimates By 14% - Yahoo Finance
Stifel Nicolaus Initiates Coverage on NewAmsterdam Pharma With Buy Rating, $44 Price Target - marketscreener.com
Stifel Initiates Coverage on NewAmsterdam Pharma (NAMS) with Pos - GuruFocus
Stifel initiates NewAmsterdam stock with Buy rating, $44 target - Investing.com
NewAmsterdam Pharma (NAMS) Reveals Alzheimer's Biomarker Data fr - GuruFocus
Analyst Says NewAmsterdam Stock Has Over 100% Upside, Citing 90% Success Probability For Obicetrapib - Benzinga
NewAmsterdam Says Obicetrapib Shows 'Significant' Reduction in Alzheimer's Biomarker; Shares Rise - marketscreener.com
NewAmsterdam reports Alzheimer’s biomarker reduction - Investing.com
NewAmsterdam Pharma (NAMS) Reveals Alzheimer's Biomarker Data from Key Trial | NAMS Stock News - GuruFocus
NewAmsterdam Pharma Reveals Positive Topline Data From BROADWAY Clinical Trial - Nasdaq
NewAmsterdam reports Alzheimer’s biomarker reduction By Investing.com - Investing.com India
NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial - GlobeNewswire
NewAmsterdam Pharma Company N.V. Announces Positive Topline Alzheimer's Disease Data from Br Broadway Clinical Trial - marketscreener.com
Bank of America Corp DE Grows Stock Position in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
NewAmsterdam Pharma Approves Key Proposals at AGM - TipRanks
NewAmsterdam Pharma to Host R&D Day on June 11, 2025 - GlobeNewswire
NewAmsterdam Pharma (NASDAQ:NAMS) Now Covered by Cantor Fitzgerald - Defense World
NewAmsterdam Pharma R&D Day: Key Pipeline Updates Coming for Revolutionary Cardiovascular Treatments - Stock Titan
NewAmsterdam Pharma (NAMS) versus Its Rivals Head-To-Head Review - Defense World
NewAmsterdam Pharma (NAMS) Receives Overweight Rating from Canto - GuruFocus
Cantor Fitzgerald initiates overweight rating for NewAmsterdam Pharma stock - Investing.com
Cantor Fitzgerald initiates overweight rating for NewAmsterdam Pharma stock By Investing.com - Investing.com India
Cantor Fitzgerald Initiates NewAmsterdam Pharma Overweight With $42 Price Target - marketscreener.com
RBC Capital maintains outperform rating for NewAmsterdam Pharma stock By Investing.com - Investing.com Canada
RBC Capital maintains outperform rating for NewAmsterdam Pharma stock - Investing.com
1.11%
1.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):